Chandrakala Shanmukhaiah
Overview
Explore the profile of Chandrakala Shanmukhaiah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kulkarni B, Shanmukhaiah C, Ghargi K, Pandey P, Kharat S, Pawar P, et al.
Blood Coagul Fibrinolysis
. 2025 Feb;
PMID: 39973821
We present a unique case of severe factor XII (FXII) deficiency in a mild hemophilia A patient. The co-occurrence of these two inherited coagulation disorders poses laboratory diagnostic challenges. We...
2.
Shah A, Khuba S, Kumar C S, Shanmukhaiah C, George M, Dhangar S, et al.
J Hum Genet
. 2025 Feb;
70(4):207-213.
PMID: 39939801
Cobalamin (Cbl) metabolism deficiencies are a heterogeneous group (CblA, CblB, CblC, CblD, CblE, CblF, CblG) of autosomal recessive disorders. CblF deficiency occurs due to mutations in LMBRD1 gene, causing variable...
3.
Kawankar N, Shanmukhaiah C, Kulkarni B
Br J Haematol
. 2024 Dec;
206(2):777-780.
PMID: 39711203
No abstract available.
4.
Nair S, Raghavendra P, Nathan M, Haribalakrishna A, Shanmukhaiah C
Neoreviews
. 2024 Aug;
25(9):e582-e585.
PMID: 39217131
No abstract available.
5.
Dongerdiye R, Kedar P, Saptarshi A, Sampagar A, Shanmukhaiah C, Mudaliar S, et al.
Ann Hematol
. 2024 Aug;
103(10):3987-3998.
PMID: 39196378
Sideroblastic anaemias are a diverse group of congenital and acquired bone marrow failure disorders marked by the presence of ring sideroblasts, ineffective erythropoiesis, and systemic iron overload. Congenital Sideroblastic anaemia...
6.
Gupta M, Shanmukhaiah C, Vundinti B, Jose A, Tiwari S, Bhowmick A, et al.
Clin Exp Immunol
. 2024 Aug;
218(3):291-299.
PMID: 39136361
Acquired aplastic anemia (AA) often results from immune destruction of hematopoietic stem and progenitor cells. However, only 60%-70% of patients with AA respond to immunosuppressive therapy (IST). There is a...
7.
Edamadaka Y, Parghane R, Sahu S, Lad S, Kamaldeep , Wanage G, et al.
Nucl Med Commun
. 2024 Jul;
45(10):823-834.
PMID: 38975801
Objective: The aim of this study was to evaluate the biodistribution and dosimetry of lutetium-177-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid ( 177 Lu-DOTA)-rituximab in CD20 + non-Hodgkin's lymphoma and other hematological malignancies treated with...
8.
Maurya N, Shanmukhaiah C, Dhangar S, Madkaikar M, Vundinti B
Oncology
. 2024 Mar;
102(10):897-906.
PMID: 38442690
Introduction: Myelodysplastic syndrome (MDS) is a heterogeneous disease characterized by cytopenia, marrow dysplasia and has a propensity to develop into acute myeloid leukemia. The disease progression is majorly affected by...
9.
Patil R, Shanmukhaiah C, Gogtay N, Pandey P, Patil K, Jijina F, et al.
J Thromb Haemost
. 2023 Dec;
22(4):1024-1030.
PMID: 38160726
Background: Low-dose emicizumab can potentially offer a cost-effective treatment option in persons with hemophilia A, especially in developing countries. Objectives: To compare the efficacy and safety of low-dose emicizumab with...
10.
Seth T, John M, Chakrabarti P, Shanmukhaiah C, Verma S, Radhakrishnan N, et al.
Haemophilia
. 2023 Dec;
30(2):426-436.
PMID: 38147060
Introduction: Emicizumab is the initial subcutaneously administered bispecific antibody approved as a prophylactic treatment for patients with haemophilia A (PwHA). Aim: This study assessed the economic evaluation of emicizumab treatment...